skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

15370

Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis



Review

(3462) Total Article Views


Authors: Pitari GM


Video abstract presented by Giovanni M Pitari
Views: 351

Published Date April 2013 Volume 2013:7 Pages 351 - 360
DOI: http://dx.doi.org/10.2147/DDDT.S32252

Giovanni M Pitari

Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA

Abstract: Agonists of the transmembrane intestinal receptor guanylyl cyclase C (GCC) have recently attracted interest as promising human therapeutics. Peptide ligands that can specifically induce GCC signaling in the intestine include endogenous hormones guanylin and uroguanylin, diarrheagenic bacterial enterotoxins (ST), and synthetic drugs linaclotide, plecanatide, and SP-333. These agonists bind to GCC at intestinal epithelial surfaces and activate the receptor’s intracellular catalytic domain, an event initiating discrete biological responses upon conversion of guanosine-5'-triphosphate to cyclic guanosine monophosphate. A principal action of GCC agonists in the colon is the promotion of mucosal homeostasis and its dependent barrier function. Herein, GCC agonists are being developed as new medications to treat inflammatory bowel diseases, pathological conditions characterized by mucosal barrier hyperpermeability, abnormal immune reactions, and chronic local inflammation. This review will present important concepts underlying the pharmacology and therapeutic utility of GCC agonists for patients with ulcerative colitis, one of the most prevalent inflammatory bowel disease disorders.

Keywords: inflammatory bowel disease, GCC agonists, cyclic GMP



Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read: